AQR Capital Management
TERN

AQR Capital Management’s Terns Pharmaceuticals TERN Stock Holding History

AQR Capital Management’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.32M Buy
176,773
+130,449
+282% +$5.36M ﹤0.01% 1374
2025
Q4 		$1.87M Buy
46,324
+6,140
+15% +$142K ﹤0.01% 2160
2025
Q3 		$302K Buy
40,184
+3,210
+9% +$20.5K ﹤0.01% 3079
2025
Q2 		$138K Buy
+36,974
New +$115K ﹤0.01% 3128
2025
Q1 		– Sell
-16,868
Closed -$93.4K – 3198
2024
Q4 		$93.4K Buy
+16,868
New +$114K ﹤0.01% 2771
2023
Q4 		– Sell
-17,014
Closed -$85.6K – 2445
2023
Q3 		$85.6K Sell
17,014
-1,049
-6% -$6.66K ﹤0.01% 2241
2023
Q2 		$158K Buy
+18,063
New +$211K ﹤0.01% 2107

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

AQR Capital Management's TERN Position: Q1 2026 in Review

AQR Capital Management increased its Terns Pharmaceuticals (TERN) stake by 282% in Q1 2026, buying an estimated $5.36M and bringing the position to 176,773 shares worth $9.32M. The position accounts for ﹤0.01% of the portfolio, ranked #1374.

AQR Capital Management first reported a position in TERN in Q2 2023 and has held it in 7 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • AQR Capital Management held 176,773 shares of Terns Pharmaceuticals worth $9.32M as of Q1 2026.
  • AQR Capital Management bought 130,449 Terns Pharmaceuticals shares in Q1 2026, an estimated $5.36M.
  • Terns Pharmaceuticals made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #1374 holding.
  • AQR Capital Management first reported a position in Terns Pharmaceuticals in Q2 2023 and has held it in 7 quarters since.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.